Advances in the anti-tumor effects of cholera toxin

doi:10.11958/20253460

Abstract

Abstract:

Cholera toxin is an AB5-type toxin secreted by vibrio cholerae and has the ability to regulate immunity. Research has found that cholera toxin has potential anti-cancer effects. It not only inhibits cell proliferation by suppressing growth factor signaling or triggering apoptosis, but also acts as an immunomodulator by mediating inflammatory responses and regulating the immune system to inhibit tumor occurrence and development. Additionally, cholera toxin can also indirectly exert anti-tumor effects by assisting in targeted drug delivery and serving as an adjuvant in vaccines. This article reviews the role of cholera toxin in tumors, providing new ideas for cancer prevention and treatment.

Key words: cholera toxin, neoplasms, adjuvants, immunologic, vaccines, cell proliferation, immunomodulation

CLC Number:

R730.1

Figures/Tables 1

References 39

[1]	张希, 杨雷, 刘硕, 等. 2022年全球恶性肿瘤统计报告解读[J]. 中华肿瘤杂志, 2024, 46(7):710-721.
	ZHANG X, YANG L, LIU S, et al. Interpretation on the report of global cancer statistics 2022[J]. Chin J Oncol, 2024, 46(7):710-721. doi:10.3760/cma.j.cn112152-20240416-00152.
[2]	HANAHAN D. Hallmarks of cancer:New dimensions[J]. Cancer Discov, 2022, 12(1):31-46. doi:10.1158/2159-8290.CD-21-1059.
[3]	张兴隆, 何红梅, 张静, 等. 人工胸水技术联合射频消融术对膈顶部肝癌患者的临床疗效[J]. 天津医药, 2025, 53(8):856-859.
	ZHANG X L, HE H M, ZHANG J, et al. The clinical efficacy of artificial pleural effusion combined with radiofrequency ablation in patients with phrenic top liver cancer[J]. Tianjin Med J, 2025, 53(8):856-859. doi:10.11958/20250709.
[4]	SHARMA P C, SHARMA D, SHARMA A, et al. Recent advances in microbial toxin-related strategies to combat cancer[J]. Semin Cancer Biol, 2022, 86(Pt 3):753-768. doi:10.1016/j.semcancer.2021.07.007.
[5]	CHOWDHURY F, ROSS A G, ISLAM M T, et al. Diagnosis,management,and future control of cholera[J]. Clin Microbiol Rev, 2022, 35(3):e0021121. doi:10.1128/cmr.00211-21.
[6]	VERJAN GARCIA N, SANTISTEBAN CELIS I C, DENT M, et al. Characterization and utility of two monoclonal antibodies to cholera toxin B subunit[J]. Sci Rep, 2023, 13(1):4305. doi:10.1038/s41598-023-30834-2.
[7]	KAUR G, VIALLET J, LABORDA J, et al. Growth inhibition by cholera toxin of human lung carcinoma cell lines:correlation with GM1 ganglioside expression[J]. Cancer Res, 1992, 52(12):3340-3346.
[8]	LI Y, YIN W, WANG X, et al. Cholera toxin induces malignant glioma cell differentiation via the PKA/CREB pathway[J]. Proc Natl Acad Sci U S A, 2007, 104(33):13438-13443. doi:10.1073/pnas.0701990104.
[9]	SHU M, ZHOU Y, ZHU W, et al. Activation of a pro-survival pathway IL-6/JAK2/STAT3 contributes to glial fibrillary acidic protein induction during the cholera toxin-induced differentiation of C6 malignant glioma cells[J]. Mol Oncol, 2011, 5(3):265-272. doi:10.1016/j.molonc.2011.03.003.
[10]	XIA Q, DENG A M, WU S S, et al. Cholera toxin inhibits human hepatocarcinoma cell proliferation in vitro via suppressing ATX/LPA axis[J]. Acta Pharmacol Sin, 2011, 32(8):1055-1062. doi:10.1038/aps.2011.31.
[11]	ZHENG X, OU Y, SHU M, et al. Cholera toxin,a typical protein kinase A activator,induces G1 phase growth arrest in human bladder transitional cell carcinoma cells via inhibiting the c-Raf/MEK/ERK signaling pathway[J]. Mol Med Rep, 2014, 9(5):1773-1779. doi:10.3892/mmr.2014.2054.
[12]	MEUNIER M, SPILLMANN A, ROUSSEAUX C, et al. An oral cholera vaccine in the prevention and/or treatment of inflammatory bowel disease[J]. PLoS One, 2023, 18(8):e0283489. doi:10.1371/journal.pone.0283489.
[13]	DOULBERIS M, ANGELOPOULOU K, KALDRYMIDOU E, et al. Cholera-toxin suppresses carcinogenesis in a mouse model of inflammation-driven sporadic colon cancer[J]. Carcinogenesis, 2015, 36(2):280-290. doi:10.1093/carcin/bgu325.
[14]	STRATMANN T. Cholera toxin subunit B as adjuvant--an accelerator in protective immunity and a break in autoimmunity[J]. Vaccines(Basel), 2015, 3(3):579-596. doi:10.3390/vaccines3030579.
[15]	ISOMURA I, YASUDA Y, TSUJIMURA K, et al. Recombinant cholera toxin B subunit activates dendritic cells and enhances antitumor immunity[J]. Microbiol Immunol, 2005, 49(1):79-87. doi:10.1111/j.1348-0421.2005.tb03632.x.
[16]	OCHANDO J, MULDER W, MADSEN J C, et al. Trained immunity-basic concepts and contributions to immunopathology[J]. Nat Rev Nephrol, 2023, 19(1):23-37. doi:10.1038/s41581-022-00633-5.
[17]	TEPALE-SEGURA A, GAJÓN J A, MUÑOZ-CRUZ S, et al. The cholera toxin B subunit induces trained immunity in dendritic cells and promotes CD8 T cell antitumor immunity[J]. Front Immunol, 2024, 15:1362289. doi:10.3389/fimmu.2024.1362289.
[18]	BALDAUF K J, ROYAL J M, KOUOKAM J C, et al. Oral administration of a recombinant cholera toxin B subunit promotes mucosal healing in the colon[J]. Mucosal Immunol, 2017, 10(4):887-900. doi:10.1038/mi.2016.95.
[19]	GUAN J, QIAN J, ZHAN C. Preparation of cholera toxin subunit B functionalized nanoparticles for targeted therapy of glioblastoma[J]. Methods Mol Biol, 2020,2059:207-212. doi:10.1007/978-1-4939-9798-5_10.
[20]	GUAN J, ZHANG Z, HU X, et al. Cholera toxin subunit B enabled multifunctional glioma-targeted drug delivery[J]. Adv Healthc Mater, 2017, 6(23):1700709. doi:10.1002/adhm.201700709.
[21]	ZHANG X, TANG W, WEN H, et al. Evaluation of CTB-sLip for targeting lung metastasis of colorectal cancer[J]. Pharmaceutics, 2022, 14(4):868. doi:10.3390/pharmaceutics14040868.
[22]	LIN Z, TANG Y, CHEN Z, et al. Soluble CD80 oral delivery by recombinant Lactococcus suppresses tumor growth by enhancing antitumor immunity[J]. Bioeng Transl Med, 2023, 8(4):e10533. doi:10.1002/btm2.10533.
[23]	KACZMAREK M, POZNAŃSKA J, FECHNER F, et al. Cancer vaccine therapeutics:limitations and effectiveness-A literature review[J]. Cells, 2023, 12(17):2159. doi:10.3390/cells12172159.
[24]	ZHAO T, CAI Y, JIANG Y, et al. Vaccine adjuvants:mechanisms and platforms[J]. Signal Transduct Target Ther, 2023, 8(1):283. doi:10.1038/s41392-023-01557-7.
[25]	ZHOU Z, DONG H, HUANG Y, et al. Recombinant Bacillus subtilis spores expressing cholera toxin B subunit and Helicobacter pylori urease B confer protection against H. pylori in mice[J]. J Med Microbiol, 2017, 66(1):83-89. doi:10.1099/jmm.0.000404.
[26]	LV X, YANG J, SONG H, et al. Therapeutic efficacy of the multi-epitope vaccine CTB-UE against Helicobacter pylori infection in a Mongolian gerbil model and its microRNA-155-associated immuno-protective mechanism[J]. Vaccine, 2014, 32(41):5343-5352. doi:10.1016/j.vaccine.2014.07.041.
[27]	LIN D, HE H, SUN J, et al. Co-delivery of PSMA antigen epitope and mGM-CSF with a cholera toxin-like chimeric protein suppressed prostate tumor growth via activating dendritic cells and promoting CTL responses[J]. Vaccine, 2021, 39(11):1609-1620. doi:10.1016/j.vaccine.2021.02.002.
[28]	HE X, FAN K, GONG H, et al. Mechanism study of cross presentation of exogenous antigen induced by cholera toxin-like chimeric protein[J]. Vaccine, 2024, 42(7):1549-1560. doi:10.1016/j.vaccine.2024.01.075.
[29]	AFALONIATI H, AINDELIS G, SPYRIDOPOULOU K, et al. Peri-weaning cholera toxin consumption suppresses chemically-induced carcinogenesis in mice[J]. Int J Cancer, 2024, 154(6):1097-1110. doi:10.1002/ijc.34816.
[30]	SIT B, FAKOYA B, WALDOR M K. Emerging concepts in cholera vaccine design[J]. Annu Rev Microbiol, 2022, 76:681-702. doi:10.1146/annurev-micro-041320-033201.
[31]	SONG K R, LIM J K, PARK S E, et al. Oral cholera vaccine efficacy and effectiveness[J]. Vaccines(Basel), 2021, 9(12):1482. doi:10.3390/vaccines9121482.
[32]	MONTERO D A, VIDAL R M, VELASCO J, et al. Vibrio cholerae,classification,pathogenesis,immune response,and trends in vaccine development[J]. Front Med(Lausanne), 2023, 10:1155751. doi:10.3389/fmed.2023.1155751.
[33]	JI J, SUNDQUIST J, SUNDQUIST K. Cholera vaccine use is associated with a reduced risk of death in patients with colorectal cancer:A population-based study[J]. Gastroenterology, 2018, 154(1):86-92.e1. doi:10.1053/j.gastro.2017.09.009.
[34]	ZHENG G, SUNDQUIST J, SUNDQUIST K, et al. Association of post-diagnostic use of cholera vaccine with survival outcome in breast cancer patients[J]. Br J Cancer, 2021, 124(2):506-512. doi:10.1038/s41416-020-01108-9.
[35]	JI J, SUNDQUIST J, SUNDQUIST K. Association between post-diagnostic use of cholera vaccine and risk of death in prostate cancer patients[J]. Nat Commun, 2018, 9(1):2367. doi:10.1038/s41467-018-04814-4.
[36]	SAIF-UR-RAHMAN K M, MAMUN R, HASAN M, et al. Oral killed cholera vaccines for preventing cholera[J]. Cochrane Database Syst Rev, 2024, 1(1):CD014573. doi:10.1002/14651858.CD014573.
[37]	COLLINS J P, RYAN E T, WONG K K, et al. Cholera vaccine:Recommendations of the Advisory Committee on Immunization Practices,2022[J]. MMWR Recomm Rep, 2022, 71(2):1-8. doi:10.15585/mmwr.rr7102a1.
[38]	EL HAYEK P, BOUERI M, NASR L, et al. Cholera infection risks and cholera vaccine safety in pregnancy[J]. Infect Dis Obstet Gynecol, 2023, 2023:4563797. doi:10.1155/2023/4563797.
[39]	YUKI Y, NOJIMA M, KASHIMA K, et al. Oral MucoRice-CTB vaccine is safe and immunogenic in healthy US adults[J]. Vaccine, 2022, 40(24):3372-3379. doi:10.1016/j.vaccine.2022.04.051.